Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of the year. Since then, KNSA shares have decreased by 5.7% and is now trading at $14.12.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our KNSA earnings forecast.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its earnings results on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to analyst estimates of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 80.53% and a negative trailing twelve-month return on equity of 15.66%.

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (1.00%), Allspring Global Investments Holdings LLC (0.31%), Hennion & Walsh Asset Management Inc. (0.11%), Strs Ohio (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry D Quart, John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $14.12.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $981.76 million and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or $2.00 on an earnings per share basis.

The company employs 215 workers across the globe.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.